NICE green light a win for Lilly in RA market

07:48 EDT 30 Jun 2017 | pharmaphorum

Eli Lilly’s Olumiant (baricitinib) rheumatoid arthritis pill has passed a major market hurdle after gaining NICE approval. The cost-effectiveness body recommended the drug after Lilly offered a confidential discount to the list price of aroun...

Original Article: NICE green light a win for Lilly in RA market


More From BioPortfolio on "NICE green light a win for Lilly in RA market"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...